Skip to main content
. Author manuscript; available in PMC: 2021 Feb 1.
Published in final edited form as: Leuk Lymphoma. 2019 Oct 16;61(2):309–317. doi: 10.1080/10428194.2019.1672052

Table 4.

Vorinostat pharmacokinetic parameters by schedule and dose level

Vorinostat
(mg)		 Alisertib
(mg)		 Cmax
(ng/mL)		 Tmax
(h)		 AUC0-tau
(μg/mL•h)		 Cl/F
(L/h)		 t½
(h)		 N
Schedule I
200 30 504 1.00 1.40 143 1.73 1
200 40 335 (148) 0.98 (0.04) 0.956 (0.503) 243 (128) 2.31 (1.19) 2
200 All 391 (143) 0.98 (0.03) 1.10 (0.44) 210 (107) 2.12 (0.91) 3
400 30 806 (582) 2.58 (1.86) 2.94 (1.43) 163 (70) 2.61 (0.99) 6
All All 2.05 (1.67) 180 (82) 2.43 (0.93) 9
 Schedule II
200 20 318 (216) 2.25 (1.58) 1.03 (0.54) 369 (504) 2.16 (1.29) 18
200 30 324 (132) 2.49 (1.76) 1.01 (0.35) 219 (79) 2.29 (1.06) 6
200 All 319 (196) 2.31 (1.59) 1.03 (0.49) 331 (440) 2.19 (1.21) 24
 Both Schedules
All 20 318 (216) 2.25 (1.58) 1.03 (0.54) 369 (504) 2.16 (1.29) 18
All 30 560 (455) 2.42 (1.71) 1.85 (1.32) 189 (75) 2.38 (0.97) 13
All 40 335 (148) 0.98 (0.04) 0.956 (0.503) 243 (128) 2.31 (1.19) 2
All All 2.24 (1.59) 293 (387) 2.25 (1.14) 33

Mean (standard deviation).

Median extrapolated portion of AUC0-tau was 0.51 % (range 0-45%).